Thermo Fisher Expands Drug Development Platform at Industry Conference
Thermo Fisher Scientific is introducing enhanced capabilities and new solutions designed to streamline the pharmaceutical and biotechnology development process at the CPHI Milan 2026 conference. The company unveiled OSD Express, a new offering intended to improve predictability in drug development. These expanded capabilities aim to help companies reduce friction in their commercialization pathways.
Thermo Fisher Scientific is leveraging a major pharmaceutical industry conference to demonstrate its commitment to modernizing drug development infrastructure. The company recognizes that biotech and pharmaceutical organizations face mounting complexity in bringing treatments from research to market, with numerous regulatory and operational hurdles creating delays and inefficiencies.
The introduction of OSD Express represents a strategic effort to address these bottlenecks through standardized solutions. By offering defined pathways and enhanced capabilities, Thermo Fisher aims to help development teams move faster and with greater confidence in their commercialization strategies.
This expansion of drug development services could affect pharmaceutical companies by potentially accelerating time-to-market for new medications, which may ultimately benefit patients awaiting treatments. Biotech firms might gain competitive advantages through reduced operational friction. However, the real-world impact depends on adoption rates and whether these platforms deliver promised efficiency gains, making outcomes difficult to predict without post-deployment data.